DeNoble, V.J., Repetti, S.J., Gelpke, L.W., Wood, L.M., Keim, K.L. "Nootropic Effects on Scopolamine-Induced and Hypoxia-Induced Retrieval Deficits of a Step-Through Passive Avoidance Response in Rats." Pharmacology Biochemistry & Behavior. 1986, Vol. 24, pp. 1123-8.

Hadjiev, D., Yancheva, S. "Rheoencephalographic and Psychologic Studies with Ethyl Apovincaminate in Cerebral Vascular Insufficiency." Arzneimittelforschung. 1976, Vol. 26, pp. 1947-50.

Otomo, E., Atarashi, J., Araki, G., Ito, E., Omae, T., Kuzuya, F., Nukada, T., Ebi, O. "Comparison of Vinpocetine with Ifenprodil Tartrate and Dihydroergotoxine Mesylate Treatment and Results of Long-Term Treatment with Vinpocetine." Current Therapeutic Research. 1985, Vol. 37, No. 5, pp. 811-21.

Pelton, R., Pelton, T.C. Mind Food & Smart Pills. New York: Doubleday, 1989.

Subhan, Z., Hindmarch, I. "Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers." European Journal of Clinical Pharmacology. 1985, Vol. 28, pp. 567-71.

Dean MD, W., Morgenthaler, J. Smart Drugs and Nutrients: How to Improve Your Memory and Increase Your Intelligence Using the Latest Discoveries in Neuroscience. California: B&J Publications, 1991.

Kiss B, Karpati E. Mechanism of action of vinpocetine [in Hungarian; English abstract]. Acta Pharm Hung. 1996;66:213–214.

Miyazaki M. The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology. 1995;46:53–58.

Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol. 1999;55:349–352.

Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991;6:31–43.

Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987;35:425–430.

Dragunow M, Faull RL. Neuroprotective effects of adenosine. Trends Pharmacol Sci. 1988;9:193–194.

Fenzl E, Apecechea M, Schaltenbrand R, et al. Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. In: Krieglstein J, ed. Pharmacology of Cerebral Ischemia: Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia.New York, NY: Elsevier Science Publishers; 1986:430–434.

Manconi E, Binaghi F, Pitzus F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenrative origin. Curr Ther Res Clin Exp. 1986;30:702–709. Cited by: Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991;6:31–43.

Peruzza M, DeJacobis M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther. 1986;3:201–209. Cited by: Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991;6:31–43.

Blaha L, Erzigkeit H, Adamczyk A, et al. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum Psychopharmacol.1989;4:103–111. Cited by: Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991;6:31–43.

Feigin VL, Doronin BM, Popova TF, et al. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001;8:81–85.

Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol. 1999;55:349–352.

Lohmann A, Dingler E, Sommer W, et al. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung. 1992;42:914–917.

Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol. 1990;28:323–328.

Shimizu Y, Saitoh K, Nakayama M, et al. Agranulocytosis induced by vinpocetine.

Kagan VE, Shvedova A, Serbinova E, et al. Dihydrolipoic acid—a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl, and chromanoxyl radicals. Biochem Pharmacol. 1992;44:1637–1649.

Matsugo S, Yan LJ, Han D, et al. Elucidation of antioxidant activity of alpha-lipoic acid toward hydroxyl radical. Biochem Biophys Res Commun. 1995;208:161–167.

Packer L, Witt EH, Tritschler HJ. Alpha–lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227–250.

Podda M, Tritschler HJ, Ulrich H, et al. Alpha–lipoic acid supplementation prevents symptoms of vitamin E deficiency. Biochem Biophys Res Commun. 1994;204:98–104.

Kagan VE, Shvedova A, Serbinova E, et al. Dihydrolipoic acid—a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl, and chromanoxyl radicals. Biochem Pharmacol. 1992;44:1637–1649.

Ziegler D, Hanefeld M, Ruhnau KJ, et al. The ALADIN III Study Group. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care. 1999;22:1296–1301.

Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425–1433.

Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62–S66.

Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62–S66.

Jacob S, Henriksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha–lipoic acid. Arzneimittelforschung. 1995;45:872–874.

Kawabata T, Packer L. Alpha-lipoate can protect against glycation of serum albumin, but not low density lipoprotein. Biochem Biophys Res Commun. 1994;203:99–104.

Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995;18:1160–1167.

Suzuki YJ, Tsuchiya M, Packer L. Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun. 1992;17:211–217.

Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999;27:309–314.

Seidman MD, Khan MJ, Bai U, et al. Biologic activity of mitochondrial metabolites on aging and age-related hearing loss. Am J Otol. 2000;21:161–167.

Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Diabetes Care. 1999;22:1296–1301.

Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425–1433.

Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62–S66.

Kahler W, Kuklinski B, Ruhlmann C, et al. Diabetes mellitus—a free radical–associated disease. Results of adjuvant antioxidant supplementation [in German; English abstract]. Z Gesamte Inn Med. 1993;48:223–232.

Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425–1433.

Packer L, Witt EH, Tritschler HJ. Alpha–lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227–250.

Ruhnau KJ, Meissnert HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16:1040–1043.

Hounsom L, Horrobin DF, Tritschler H, et al. A lipoic acid–gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia. 1998;41:839–843.

Cameron NE, Cotter MA, Horrobin DH, et al. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: Interaction with essential fatty acids. Diabetologia. 1998;41:390–399.

Zeisel SH. Choline: an important nutrient in brain development, liver function and carcinogenesis. J Am Coll Nutr. 1992;11:473–481.

Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J. 1991;5:2093–2098.

Jacob RA, Jenden DJ, Allman-Farinelli MA, et al. Folate nutriture alters choline status of women and men fed low choline diets. J Nutr. 1999;129:712–717.

Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J. 1991;5:2093–2098.

[No authors listed]. Choline: a conditionally essential nutrient for humans. Nutr Rev. 1992;50:112–114.

Leathwood PD, Schlosser B. Phosphatidylcholine, choline and cholinergic function. Int J Vitam Nutr Res Suppl. 1986;29:49–67.

Sanchez CJ, Hooper E, Garry PJ, et al. The relationship between dietary intake of choline, choline serum levels, and cognitive function in healthy elderly persons. J Am Geriatr Soc. 1984;32:208–212.

Zeisel SH. Choline: an important nutrient in brain development, liver function and carcinogenesis. J Am Coll Nutr. 1992;11:473–481.

Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry. 1978;13:23–49.

Hirsch MJ, Growdon JH, Wurtman RJ. Relations between dietary choline or lecithin intake, serum choline levels, and various metabolic indices. Metabolism. 1978;27:953–960.

Wood JL, Allison RG. Effects of consumption of choline and lecithin on neurological and cardiovascular systems. Fed Proc. 1982;41:3015–3021.

Russell RW. Continuing the search for cholinergic factors in cognitive dysfunction. Life Sci. 1996;58:1965–1970.

Wurtman RJ, Growdon JH. Dietary enhancement of CNS neurotransmitters. Hosp Pract. 1978;13:71–77.

Zeisel SH. Dietary influences on neurotransmission. Adv Pediatr. 1986;33:23–47.

Heyman A, Schmechel D, Wilkinson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm Suppl. 1987;24:279–286.

Weintraub S, Mesulan MM, Auty R, et al. Lecithin in the treatment of Alzheimer's disease. Arch Neurol. 1983;40:527–528.

Etienne P, Dastoor D, Gauthier S, et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurology. 1981;31:1552–1554.

Gauthier S, Bouchard R, Bacher Y, et al. Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can J Neurol Sci. 1989;16:543–546.

Leathwood PD, Schlosser B. Phosphatidylcholine, choline and cholinergic function. Int J Vitam Nutr Res Suppl. 1986;29:49–67.

Sanchez CJ, Hooper E, Garry PJ, et al. The relationship between dietary intake of choline, choline serum levels, and cognitive function in healthy elderly persons. J Am Geriatr Soc. 1984;32:208–212.

Harris CM, Dysken MW, Fovall P, et al. Effect of lecithin on memory in normal adults. Am J Psychiatry. 1983;140:1010–1012.

Stoll AL, Sachs GS, Cohen BM, et al. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry. 1996;40:382–388.

Cohen BM, Lipinski JF, Altesman RI, et al. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry. 1982;139:1162–1164.

Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry. 1990;51:149–153.

Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry. 1978;13:23–49.

Brook JG, Linn S, Aviram M, et al. Dietary soya lecithin decreases plasma triglyceride levels and inhibits collagen- and ADP-induced platelet aggregation. Biochem Med Metab Biol. 1986;35:31–39.

Wojcicki J, Pawlik A, Samochowiec L, et al. Clinical evaluation of lecithin as a lipid-lowering agent. Phytotherapy Res. 1995;9:597–599.

Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J. 1991;5:2093–2098.

Olszewski AJ, Szostak WB, Bialkowska M, et al. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis. 1989;75:1–6.

Dudman NP, Wilcken DE, Wang J, et al. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb. 1993;13:1253–1260.

Bogden JD, Kemp FW, Han S, et al. Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. Am J Clin Nutr. 2000;72:809–815.

Misra S, Ahn C, Ament ME, et al. Plasma choline concentration in children requiring long-term home parenteral nutrition: a case control study. JPEN J Parenter Enteral Nutr. 1999;23:305–308.

Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology. 1992;102:1363–1370.

Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J. 1991;5:2093–2098.

Tayek JA, Bistrian B, Sheard NF, et al. Abnormal liver function in malnourished patients receiving total parenteral nutrition: a prospective randomized study. J Am Coll Nutr. 1990;9:76–83.

Zeisel SH. Choline: an important nutrient in brain development, liver function and carcinogenesis. J Am Coll Nutr. 1992;11:473–481.

Burt ME, Hanin I, Brennan MF, et al. Choline deficiency associated with total parenteral nutrition. Lancet. 1980;2:638–639.

Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Hepatogastroenterology. 1998;45:797–804.

Guan R, Ho KY, Kang JY, et al. The effect of polyunsaturated phosphatidyl choline in the treatment of acute viral hepatitis. Aliment Pharmacol Ther. 1995;9:699–703.

Chawla RK, Wolf DC, Kutner MH, et al. Choline may be an essential nutrient in malnourished patients with cirrhosis. Gastroenterology. 1989;97:1514–1520.

Zeisel SH. Choline: an important nutrient in brain development, liver function and carcinogenesis. J Am Coll Nutr. 1992;11:473–481.

Newberne PM. Lipotropic factors and oncogenesis. Adv Exp Med Biol. 1986;206:223–251.

Wainfan E, Poirier LA. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 1992;52:S2071–S2077.

Rogers AE. Methyl donors in the diet and responses to chemical carcinogens. Am J Clin Nutr. 1995;61:S659–S665.

Heyman A, Schmechel D, Wilkinson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm Suppl. 1987;24:279–286.

Weintraub S, Mesulan MM, Auty R, et al. Lecithin in the treatment of Alzheimer's disease. Arch Neurol. 1983;40:527–528.

Etienne P, Dastoor D, Gauthier S, et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurology. 1981;31:1552–1554.

Gauthier S, Bouchard R, Bacher Y, et al. Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can J Neurol Sci. 1989;16:543–546.

Stoll AL, Sachs GS, Cohen BM, et al. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry. 1996;40:382–388.

Cohen BM, Lipinski JF, Altesman RI, et al. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry. 1982;139:1162–1164.

Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry. 1990;51:149–153.

Domino EF. Monoamine oxidase, tobacco smoking, and psychiatric disorders. Biol Psychiatry. 1996;40:433–434.

Bartus RT, Dean RL, Goas JA, et al. Age-related changes in passive avoidance retention: modulation with dietary choline. Science. 1980;209:301–303.

Meck WH, Williams CL. Simultaneous temporal processing is sensitive to prenatal choline availability in mature and aged rats. Neuroreport. 1997;8:3045–3051.

Sanchez CJ, Hooper E, Garry PJ, et al. The relationship between dietary intake of choline, choline serum levels, and cognitive function in healthy elderly persons. J Am Geriatr Soc. 1984;32:208–212.

Harris CM, Dysken MW, Fovall P, et al. Effect of lecithin on memory in normal adults. Am J Psychiatry. 1983;140:1010–1012.

Toffano G, Leon A, Benvegnu D. Effect of brain cortex phospholipids on catechol-amine content of mouse brain. Pharmacol Res Commun. 1976;8:581–590.

LaBrake CC, Fung LW. Phospholipid vesicles promote human hemoglobin oxidation. J Biol Chem. 1992;267:16703–16711.

Orlando P, Cerrito F, Zirili P. The fate of doubly-labelled brain phospholipids administered to mice. Farmaco. 1975;30:451–458.

Gindin J, et al. The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly. Rehovot, Israel. Geriatric Institute for Education and Research and Dept. of Geriatrics, Kaplan Hospital, 1995.

Crook TH III, Adderly BD. The Memory Cure: The Safe, Scientifically Proven Breakthrough That Can Slow, Halt, Or Even Reverse Age-Related Memory Loss. New York, NY: Pocket Books; 1998:71, 72.

Gaby AR. Don't believe everything you read. Townsend Letter for Doctors and Patients. May 1997:122–123.

Gindin J, et al. The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly. Rehovot, Israel. Geriatric Institute for Education and Research and Dept. of Geriatrics, Kaplan Hospital, 1995.

Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: Results of a multicenter study. Psychopharmacol Bull. 1988;24:130–134.

Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41:644–649.

Crook T, Petrie W, Wells C, et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. 1992;28:61–66.

Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. 1986;73:136–140.

Engel RR, Satzger W, Gunther W, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol. 1992;2:149–155.

Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in Parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res. 1989;317:1235–1246.

Nerozzi D, Aceti F, Melia E, et al. Phosphatidylserine and memory disorders in the aged [in Italian; English abstract]. Clin Ther. 1987;120:399–404.

Palmieri G, Palmieri R, Inzoli MR, et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J. 1987;24:73–83.

Villardita C, Grioli S, Salmeri G, et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J. 1987;24:84–93.

Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano). 1993;5:123–133.

Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41:644–649.

Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 1990;81:265–270.

Brambilla F, Maggioni M, Panerai AE, et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology. 1996;34:18–21.

Fahey TD, Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract presented at: National Meeting of the American College of Sports Medicine;June, 1998; Orlando, Fla.

Monteleone P, Maj M, Beinat L, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42:385–388.

Fahey TD, Pearl M. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Biol Sport. 1998;15:135–144.

Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano). 1993;5:123–133.

Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: Results of a multicenter study. Psychopharmacol Bull. 1988;24:130–134.

Crook T, Petrie W, Wells C, et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. 1992;28:61–66.

Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. 1986;73:136–140.

Engel RR, Satzger W, Gunther W, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol. 1992;2:149–155.

Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in Parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res. 1989;317:1235–1246.

Nerozzi D, Aceti F, Melia E, et al. Phosphatidylserine and memory disorders in the aged [in Italian; English abstract]. Clin Ther. 1987;120:399–404.

Palmieri G, Palmieri R, Inzoli MR, et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J. 1987;24:73–83.

Villardita C, Grioli S, Salmeri G, et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J. 1987;24:84–93.

Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41:644–649.

Fahey TD, Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract presented at: National Meeting of the American College of Sports Medicine;June, 1998; Orlando, Fla.

Fahey TD, Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract presented at: National Meeting of the American College of Sports Medicine;June, 1998; Orlando, Fla.

Monteleone P, Maj M, Beinat L, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42:385–388.

Monteleone P, Maj M, Beinat L, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42:385–388.

Fahey TD, Pearl M. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Biol Sport. 1998;15:135–144.

Monteleone P, Beinat L, Tanzillo C, et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology.1990;52:243–248.

Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano). 1993;5:123–133.

Cenacchi B, Baggio C, Palm E. Human tolerability of oral phosphatidylserine assessed through laboratory examinations. Clin Trials J. 1987;24:125–130.

van den Besselaar AM. Phosphatidylethanolamine and phosphatidylserine synergistically promote heparin's anticoagulant effect. Blood Coagul Fibrinolysis. 1995;6:239–244.

Kant AK, Block G. Dietary vitamin B-6 intake and food sources in the US population: NHANES II, 1976–1980. Am J Clin Nutr. 1990;52:707–716.

van der Wielen RP, de Groot LC, van Staveren WA. Dietary intake of water soluble vitamins in elderly people living in a Western society (1980–1993). Nutr Res. 1994;14:605–638.

Albertson AM, Toblemann RC, Engstrom A, et al. Nutrient intakes of 2- to 10-year-old American children: 10-year trends. J Am Diet Assoc. 1992;92:1492–1496.

Hansen CM, Shultz TD, Kwak HK, et al. Assessment of vitamin B-6 status in young women consuming a controlled diet containing four levels of vitamin B-6 provides an estimated average requirement and recommended dietary allowance. J Nutr. 2001;131:1777–1786.

Vidrio H. Interaction with pyridoxal as a possible mechanism of hydralazine hypotension. J Cardiovasc Pharmacol. 1990;15:150–156.

Rumsby PC, Shepherd DM. The effect of penicillamine on vitamin B6 function in man. Biochem Pharmacol. 1981;30:3051–3053.

Delport R, Ubbink JB, Serfontein WJ, et al. Vitamin B6 nutritional status in asthma: the effect of theophylline therapy on plasma pyridoxal-5'-phosphate and pyridoxal levels. Int J Vitam Nutr Res. 1988;58:67–72.

Ubbink JB, Vermaak WJ, Delport R, et al. The relationship between vitamin B6 metabolism, asthma, and theophylline therapy. Ann N Y Acad Sci. 1990;585:285–294.

Delport R, Ubbink JB, Vermaak WJ, et al. Theophylline increases pyridoxal kinase activity independently from vitamin B 6 nutritional status. Res Commun Chem Pathol Pharmacol. 1993;79:325–333.

Ubbink JB, Delport R, Bissbort S, et al. Relationship between vitamin B-6 status and elevated pyridoxal kinase levels induced by theophylline therapy in humans. J Nutr. 1990;120:1352–1359.

Shimizu T, Maeda S, Mochizuki H, et al. Theophylline attenuates circulating vitamin B 6 levels in children with asthma . Pharmacology. 1994;49:392–397.

Heller CA, Friedman PA. Pyridoxine deficiency and peripheral neuropathy associated with long-term phenelzine therapy. Am J Med. 1983;75:887–888.

Heller CA, Friedman PA. Pyridoxine deficiency and peripheral neuropathy associated with long-term phenelzine therapy. Am J Med. 1983;75:887–888.

Biehl JP, Vilter RW. Effect of isoniazid on vitamin B 6 metabolism; its possible significance in producing isoniazid neuritis. Proc Soc Exp Biol Med. 1954;85:389–392.

Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980;61:191–196.

Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364.

Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995;173:881–884.

Franzblau A, Rock CL, Werner RA, et al. The relationship of vitamin B 6 status to median nerve function and carpal tunnel syndrome among active industrial workers. JOEM. 1996;38:485–491.

Ellis JM, Kishi T, Azuma J, et al. Vitamin B6 deficiency in patients with a clinical syndrome including the carpal tunnel defect. Biochemical and clinical response to therapy with pyridoxine. Res Commun Chem Pathol Pharmacol. 1976;13:743–757.

Stransky M, Rubin A, Lava NS, et al. Treatment of carpal tunnel syndrome with vitamin B6: a double-blind study. South Med J. 1989;81:841–842.

Spooner GR, Desai HB, Angel JF, et al. Using pyridoxine to treat carpal tunnel syndrome . Can Fam Physician. 1993;39:2122–2127.

Diegoli MS, da Fonseca AM, Diegoli CA, et al. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet. 1998;62:63–67.

Cohen KL, Gorecki GA, Silverstein SB, et al. Effect of pyridoxine (vitamin B6) on diabetic patients with peripheral neuropathy. J Am Podiatry Assoc. 1984;74:394–397.

McCann VJ, Davis RE. Pyridoxine and diabetic neuropathy: a double-blind controlled study. Diabetes Care. 1983;6:102–103.

Levin ER, Hanscom TA, Fisher M, et al. The influence of pyridoxine in diabetic peripheral neuropathy. Diabetes Care. 1981;4:606–609.

Parivar F, Low RK, Stoller ML. The influence of diet on urinary stone disease. J Urol. 1996;155:432–440.

Murthy MS, Farooqui S, Talwar HS, et al. Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharmacol Ther Toxicol. 1982;20:434–437.

Curhan GC, Willett WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol. 1999;10:840–845.

Curhan GC, Willett WC, Rimm EB, et al. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol. 1996;155:1847–1851.

Bell IR, Edman JS, Morrow FD, et al. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr. 1992;11:159–163.

Collipp PJ, Goldzier S III, Weiss N, et al. Pyridoxine treatment of childhood bronchial asthma. Ann Allergy. 1975;35:93–97.

Sur S, Camara M, Buchmeier A, et al. Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid-dependent asthma. Ann Allergy. 1993;70:147–152.

Bennink HJ, Schreurs WH. Improvement of oral glucose tolerance in gestational diabetes by pyridoxine. Br Med J. 1975;3:13–15.

Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am JEpidemiol. 1996;143:1244–1256.

Baum MK, Mantero-Atienza E, Shor-Posner G, et al. Association of vitamin B6 status with parameters of immune function in early HIV-1 infection. J Acquir Immune Defic Syndr. 1991;4:1122–1132.

DeVeaugh-Geiss J, Manion L. High-dose pyridoxine in tardive dyskinesia. J Clin Psychiatry. 1978;39:573–575.

Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci. 1990;52:225–232.

Lerner V, Kaptsan A, Miodownik C, et al. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neurpharmacol. 1999;22:241–243.

Ross JB, Moss MA. Relief of the photosensitivity of erythropoietic protoporphyria by pyridoxine. J Am Acad Dermatol. 1990;22:340–342.

Lewy A, Fox N. Clinical notes; new instruments and techniques: pyroxidine (B6) used in the treatment of vertigo. Arch Otolaryngol. 1947; 681–683.

Dakshinamurti K, Paulose CS, Viswanathan M. Vitamin B 6 and hypertension. Ann N Y Acad Sci. 1990;585:241–249.

Vestal RE, Eiriksson CE Jr, Musser B, et al. Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man. Circulation. 1983;67:162–171.

Bartel PR, Ubbink JB, Delport R, et al. Vitamin B-6 supplementation and theophylline - related effects in humans. Am J Clin Nutr. 1994;60:93–99.

Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985;20:467–478.

Pfeiffer SI, Norton J, Nelson L, et al. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord. 1995;25:481–493.

Barthelemy C, Garreau B, Leddet I, et al. Behavioral and biological effects of oral magnesium, vitamin B6 and combined magnesium–vitamin B6 administration in autistic children. Magnes Bull. 1981;2:150–153.

Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4:27–44.

Lelord G, Muh JP, Barthelemy C. Effects of pyridoxine and magnesium on autistic symptoms--initial observations. J Autism Dev Disord. 1981;11:219–230.

Martineau J, Garreau B, Barthelemy C, et al. Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biol Psychiatry. 1981;16:627–641.

Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978;135:472–475.

Cook R, Botting D. Use of orthomolecular therapy for those with behavioural problems and mental handicap: a review. Complement Ther Med. 1997;5:228–232.

Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. J Child Neurol. 1988;3(suppl):S68–S72.

Rimland B. Vitamin B6 versus fenfluramine: a case-study in medical bias. J Nutr Med. 1991;2:321–322.

Werbach MR. Autism. Int J Alt Complement Med. 1996;8.

Effersoe H. The effect of topical application of pyridoxine ointment on the rate of sebaceous secretion in patients with seborrheic dermatitis. Acta Derm Venereol. 1954;3:272–278.

Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364.

Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204–210.

McKinley MC, McNulty H, McPartlin J, et al. Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr. 2001;73:759–764.

Sermet A, Aybak M, Ulak G, et al. Effect of oral pyridoxine hydrochloride supplementation on in vitro platelet sensitivity to different agonists. Arzneimittelforschung. 1995;45:19–21.

Aybak M, Sermet A, Ayyildiz MO, et al. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. 1995;45:1271–1273.

Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995;173:881–884.

Diegoli MS, da Fonseca AM, Diegoli CA, et al. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet. 1998;62:63–67.

Kleijnen J, Ter Riet G, Knipschild P. Vitamin B6 in the treatment of premenstrual syndrome—a review . Br J Obstet Gynaecol. 1990;97:847–852.

Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318:1375–1381.

De Souza MC, Walker AF, Robinson PA, et al. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B 6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000;9:131–139.

Pfeiffer SI, Norton J, Nelson L, et al. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord. 1995;25:481–493.

Barthelemy C, Garreau B, Leddet I, et al. Behavioral and biological effects of oral magnesium, vitamin B6 and combined magnesium–vitamin B6 administration in autistic children. Magnes Bull. 1981;2:150–153.

Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4:27–44.

Lelord G, Muh JP, Barthelemy C. Effects of pyridoxine and magnesium on autistic symptoms–initial observations. J Autism Dev Disord. 1981;11:219–230.

Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985;20:467–478.

Martineau J, Garreau B, Barthelemy C, et al. Effects of vitamin B6 on averaged evoked potentials in infantile autism Biol Psychiatry. 1981;16:627–641.

Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985;20:467–478.

Collipp PJ, Goldzier S III, Weiss N, et al. Pyridoxine treatment of childhood bronchial asthma. Ann Allergy. 1975;35:93–97.

Sur S, Camara M, Buchmeier A, et al. Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid-dependent asthma. Ann Allergy. 1993;70:147–152.

Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35:1466–1468.

Lim D, McKay M. Food-drug interactions. Drug Information Bulletin.1995;15:UCLA Dept. of Pharmaceutical Services.

Yahr MD, Duvoisin RC. Pyridoxine and levodopa in the treatment of Parkinsonism. JAMA. 1972;220:861.

Leon AS, Spiegel HE, Thomas G, et al. Pyridoxine antagonism of levodopa in parkinsonism. JAMA. 1971;218:1924–1927.

Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B 6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158:1511–1514.

Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B 6 , Folate, Vitamin B 12 , Pantothenic Acid, Biotin, and Choline (1998). Available at www.nap.edu.

Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao Li Xue Bao. 1991;12:250–252.

Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav. 1998;60:377–386.

Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996;8:97–101.

Xiong ZQ, Tang XC. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav. 1995;51:415–419.

Zhi QX, Yi FH, XI CT. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport. 1995;6:2221–2224.

Zhu XD, Giacobini E. Second generation cholinesterase inhibitors: effect of (L)-huperzine-A on cortical biogenic amines. J Neurosci Res. 1995;41:828–835.

Zhang GB, Wang MY, Zheng JQ, et al. Facilitation of cholinergic transmission by huperzine A in toad paravertebral ganglia in vitro [in Chinese; English abstract]. Zhongguo Yao Li Xue Bao. 1994;15:158–161.

Laganiere S, Corey J, Tang XC, et al. Acute and chronic studies with the anticholinesterase Huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology. 1991;30:763–768.

Tang XC, De Sarno P, Sugaya K, et al. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res. 1989;24:276–285.

Tang XC, Han YF, Chen XP, et al. Effects of huperzine A on learning and the retrieval process of discrimination performance in rats [in Chinese]. Zhongguo Yao Li Xue Bao. 1986;7:507–511.

Guan LC, Chen SS, Lu WH, et al. Effects of huperzine A on electroencephalography power spectrum in rabbits [in Chinese; English abstract]. Zhongguo Yao Li Xue Bao. 1989;10:496–500.

Lu WH, Shou J, Tang XC. Improving effect of huperzine A on discrimination performance in aged rats and adult rats with experimental cognitive impairment [in Chinese]. Zhongguo Yao Li Xue Bao. 1988;9:11–15.

Wang YE, Feng J, Lu WH. Pharmacokinetics of huperzine A in rats and mice [in Chinese]. Zhongguo Yao Li Xue Bao. 1988;9:193–196.

Wang YE, Yue DX, Tang XC. Anti-cholinesterase activity of huperzine A [in Chinese]. Zhongguo Yao Li Xue Bao. 1986;7:110–113.

Zhu XD, Tang XC. Improvement of impaired memory in mice by huperzine A and huperzine B [in Chinese]. Zhongguo Yao Li Xue Bao. 1988;9:492–497.

Zhu XD, Tang XC. Facilitatory effects of huperzine A and B on learning and memory of spatial discrimination in mice [in Chinese]. Yao Xue Xue Bao. 1987;22:812–817.

Yan XF, Lu WH, Lou WJ, et al. Effects of huperzine A and B on skeletal muscle and the electroencephalogram [in Chinese]. Zhongguo Yao Li Xue Bao. 1987;8:117–123.

Xu SS, Goa ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao. 1995;16:391–395.

Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao Li Xue Bao. 1991;12:250–252.

Xu SS, Cai ZY, Qu ZW, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease [abstract]. Zhongguo Yao Li Xue Bao. 1999;20:486–490.

Sun QQ, Xu SS, Pan JL, et al. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students [abstract]. Zhongguo Yao Li Xue Bao. 1999;20:601–603.

Raves ML, Harel M, Pang YP, et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol. 1997;4:57–63.

Ashani Y, Peggins JO III, Doctor BP. Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys Res Commun. 1992;184:719–726.

Pang YP, Kozikowski AP. Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies. J Comput Aided Mol Des. 1994;8:669–681.

Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Avit Space Environ Med. 1995;66:313–319.

Eisenberg MD, Asnis GM, van Praag HM, et al. Effect of tyrosine on attention deficit disorder with hyperactivity. J Clin Psychiatry. 1988;49:193–195.

Reimherr FW, Wender PH, Wood RD, et al. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. Am J Psychiatry. 1987;144:1071–1073.

Wood RD, Reimherr FW, Wender PH, et al. Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacol Bull. 1985;21:146–149.

Gibson C, Gelenberg A. Tyrosine for the treatment of depression. Adv Biol Psychiatry. 1983;10:148–159.

Gelenberg AJ, Wojcik JD, Falk WE, et al. Tyrosine for depression: a double-blind trial. J Affect Disord. 1990; 19:125–132.

Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Avit Space Environ Med. 1995;66:313–319.

Gibson C, Gelenberg A. Tyrosine for the treatment of depression. Adv Biol Psychiatry. 1983;10:148–159.

Gelenberg AJ, Wojcik JD, Falk WE, et al. Tyrosine for depression: a double-blind trial. J Affect Disord. 1990; 19:125–132.

Re' O. 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Ther Res Clin Exp. 1974;16:1238–1242.

Knobel M. Approach to a combined pharmacologic therapy of childhood hyperkinesis. Behav Neuropsychiatry. 1974 Apr–1975 Mar;6:87–90.

Casey DE, Denney D. Dimethylaminoethanol in tardive dyskinesia [letter]. N Engl J Med. 1974;291:797.

Alphs L, Davis JM. Noncatecholaminergic treatments of tardive dyskinesia. J Clin Psychopharmacol. 1982;2:380–385.

Soares KV, McGrath JJ. The treatment of tardive dyskinesia—a systematic review and meta-analysis. Schizophr Res. 1999;39:1–18.

Caraceni TA, Girotti F, Celano I, et al. 2-dimethylaminoethanol (deanol) in Huntington's chorea. J Neurol Neurosurg Psychiatry. 1978;41:1114–1118.

Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch Neurol. 1977;34:756–758.

Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. Am J Psychiaty. 1981;138:970–972.

Zahniser NR, Chou D, Hanin I. Is 2-dimthylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation. J Pharmacol Exp Ther. 1977;200:545–559.

Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. Am J Psychiaty. 1981;138:970–972.

Ferris SH, Sathananthan G, Gershon S, et al. Senile dementia: treatment with Deanol. J Am Geriatr Soc. 1977;25:241–244.

Casey DE, Denney D. Dimethylaminoethanol in tardive dyskinesia [letter]. N Engl J Med. 1974;291:797.

Alphs L, Davis JM. Noncatecholaminergic treatments of tardive dyskinesia. J Clin Psychopharmacol. 1982;2:380–385.

Haug BA, Holzgraefe M. Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol). Eur Neurol. 1991;31:423–425.

Sergio W. Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. Med Hypothesis. 1988;26:255–257.

Haug BA, Holzgraefe M. Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol). Eur Neurol. 1991;31:423–425.

Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13:584–591.

van Goor L, Woiski MD, Lagaay AM, et al. Review: cobalamin deficiency and mental impairment in elderly people. Age Ageing. 1995;24:536–542.

Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc. 1992;40:1197–1204.

Yao Y, Yao SL, Yao SS, et al. Prevalence of vitamin B12 deficiency among geriatric outpatients. J Fam Pract. 1992;35:524–528.

Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin. Ann Intern Med. 1994;120:211–215.

Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13:584–591.

Streeter AM, Goulston KJ, Bathur FA, et al. Cimetidine and malabsorption of cobalamin. Dig Dis Sci. 1982;27:13–16.

Aymard JP, Aymard B, Netter P, et al. Haematological adverse effects of histamine H 2 -receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3:430–448.

Salom IL, Silvis SE, Doscherholmen A. Effect of cimetidine on the absorption of vitamin B 12 . Scand J Gastroenterol. 1982;17:129–131.

Belaiche J, Zittoun J, Marquet J, et al. Effect of ranitidine on gastric intrinsic factor and cobalamin (vitamin B 12 ) absorption [translated from French]. Gastroenterol Clin Biol. 1983;7:381–384.

Webb DI, Chodos RB, Mahar CQ, et al. Mechanism of vitamin B12 malabsorption in patients receiving colchicine. N Engl J Med.1968;279:845–850.

Adams JF, Clark JS, Ireland JT, et al. Malabsorption of vitamin B 12 and intrinsic factor secretion during biguanide therapy. Diabetologia. 1983;24:16–18.

Flippo TS, Holder WD Jr. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg. 1993;128:1391–1395.

Baum MK, Javier JJ, Mantero-Atienza E, et al. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1 infected homosexual males. J Acquir Immune Defic Syndr. 1991;4:1218–1226.

Deleu D, Louon A, Sivagnanam S, et al. Long-term effects of nitrous oxide anaesthesia on laboratory and clinical parameters in elderly Omani patients: a randomized double-blind study. J Clin Pharm Ther. 2000;25:271–277.

Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23:1227–1231.

Drug Evaluations Annual. Vol. 3. Milwaukee, Wis: American Medical Association, 1993.

Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin. Ann Intern Med. 1994;120:211–215.

Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13:584–591.

Streeter AM, Goulston KJ, Bathur FA, et al. Cimetidine and malabsorption of cobalamin. Dig Dis Sci. 1982;27:13–16.

Aymard JP, Aymard B, Netter P, et al. Haematological adverse effects of histamine H 2 -receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3:430–448.

Salom IL, Silvis SE, Doscherholmen A. Effect of cimetidine on the absorption of vitamin B 12 . Scand J Gastroenterol. 1982;17:129–131.

Belaiche J, Zittoun J, Marquet J, et al. Effect of ranitidine on secretion of gastric intrinsic factor and absorption of vitamin B 12 . Gastroenterol Clin Biol. 1983;7:381–384.

Carmel R, Gott P, Degiorgio C, et al. Abnormal P300 event-related potentials in mild, preclinical cobalamin deficiency [abstract]. Int J Hematol. 2000;72(suppl 1):207.

Louwman MW, van Dusseldorp M, van de Vijver FJ, et al. Signs of impaired cognitive function in adolescents with marginal cobalamin status. Am J Clin Nutr. 2000;72:762–769.

Elia M. Oral parenteral therapy for B12 deficiency. Lancet. 1998;352:1721–1722.

McIntyre PA, Hahn R, Masters JM, et al. Treatment of pernicious anemia with orally administered cyanocobalamin (vitamin B12). Arch Intern Med. 1960;106:280–292.

Waife SO, Jansen CJ Jr, Crabtree RE, et al. Oral vitamin B12 without intrinsic factor in the treatment of pernicious anemia. Ann Intern Med. 1963;58:810–817.

Berlin H, Berlin R, Brante G. Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. Acta Med Scand. 1968;184:247–258.

Kumamoto Y, Maruta H, Ishigami J, et al. Clinical efficacy of mecobalamin in treatment of oligozoospermia––results of double-blind comparative clinical study [in Japanese; English abstract]. Hinyokika Kiyo. 1988;34:1109–1132.

Sandler B, Faragher B. Treatment of oligospermia with vitamin B12. Infertility. 1984;7:133–138.

Wright J. Vitamin B12: Powerful protection against asthma. Int Clin Nutr Rev. 1989;9:185–188.

Rule SA, Hooker M, Costello C, et al. Serum vitamin B12 and transcobalamin levels in early HIV disease. Am J Hematol. 1994;47:167–171.

Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192–197.

Shor-Posner G, Morgan R, Wilkie F, et al. Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease. Arch Neurol. 1995;52:195–198.

Kieburtz KD, Giang DW, Schiffer RB, et al. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunction. Arch Neurol. 1991;48:312–314.

Baum MK, Shor-Posner G, Lu Y, et al. Micronutrients and HIV-1 disease progression. AIDS. 1995;9:1051–1056.

Kaji R, Kodama M, Imamura A, et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve. 1998;21:1775–1778.

Ide H, Fujiya S, Asanuma Y, et al. Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clin Ther. 1987;9:183–192.

Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg. 1992;94:105–111.

Kira J, Tobimatsu S, Goto I. Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis. Intern Med. 1994;33:82–86.

Goodkin DE, Jacobsen DW, Galvez N, et al. Serum cobalamin deficiency is uncommon in multiple sclerosis. Arch Neurol. 1994;51:1110–1114.

Baig SM, Qureshi GA, Minami M. The interrelation between the deficiency of vitamin B12 and neurotoxicity of homocysteine with nitrite in some of neurologic disorders. Biogenic Amines. 1998;14:1–14.

Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol. 1992;40:225–230.

Simpson CA, Newell DJ, Miller H. The treatment of multiple sclerosis with massive doses of hydroxocobalamin. Neurology. 1965;15:599–603.

O'Keeffe ST. Restless legs syndrome: a review. Arch Intern Med. 1996;156:243–248.

Silber MH. Restless legs syndrome. Mayo Clin Proc. 1997;72:261–264.

Shemesh Z, Attias J, Ornan M, et al. Vitamin B12 deficiency in patients with chronic tinnitus and noise-induced hearing loss. Am J Otolarygol. 1993;14:94–99.

Martin DC, Francis J, Protetch J, et al. Time dependency of cognitive recovery with cobalamin replacement: Report of a pilot study. J Am Geriatr Soc. 1992;40:168–172.

Kwok T, Tang C, Woo J, et al. Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry. 1998;13:611–616.

Teunisse S, Bollen AE, van Gool WA, et al. Dementia and subnormal levels of vitamin B12: Effects of replacement therapy on dementia. J Neurol. 1996;243:522–529.

Montes LF, Diaz ML, Lajous J, et al. Folic acid and vitamin B12 in vitiligo: a nutritional approach. Cutis. 1992;50:39–42.

Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol (Stockh). 1997;77:460–462.

Kim SM, Kim YK, Hann S-K. Serum levels of folic acid and vitamin B12 in Korean patients with vitiligo. Yonsei Med J. 1999;40:195–198.

Kumamoto Y, Maruta H, Ishigami J, et al. Clinical efficacy of mecobalamin in treatment of oligozoospermia––results of double-blind comparative clinical study [in Japanese; English abstract]. Hinyokika Kiyo. 1988;34:1109–1132.

Sheretz EF. Acneform eruption due to "megadose" vitamins B6 and B12. Cutis. 1991;48:19–20.

Braun-Falco O, Lincke H. The problem of vitamin B6/B12 acne. A contribution on acne medicamentosa [in German; English abstract]. MMW Munch Med Wochenschr. 1976;118:155–160.

Castell LM, Poortmans JR, Newsholme EA. Does glutamine have a role in reducing infections in athletes? Eur J Appl Physiol Occup Physiol. 1996;73:488–490.

Castell LM, Newsholme EA. Glutamine and the effects of exhaustive exercise upon the immune response. Can J Physiol Pharmacol. 1998;76:524–532.

Rohde T, MacLean DA, Hartkopp A, et al. The immune system and serum glutamine during a triathlon. Eur J Appl Physiol. 1996;74:428–434.

Rowbottom DG, Keast D, Morton AR, et al. The emerging role of glutamine as an indicator of exercise stress and overtraining. Sports Med. 1996;21:80–97.

Castell LM, Newsholme EA. The effects of oral glutamine supplementation on athletes after prolonged, exhaustive exercise. Nutrition. 1997;13:738–742.

Griffiths RD, Jones C, Palmer TE. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition. 1997;13:295–302.

van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet. 1993;341:1363–1365.

Zoli G, Care M, Falco F, et al. Effect of oral glutamine on intestinal permeability and nutritional status in Crohn's disease [abstract]. Gastroenterology. 1995;108:A766.

Alverdy JC. Effects of glutamine-supplemented diets on immunology of the gut. JPEN J Parenter Enteral Nutr. 1990;14(suppl 4):109S–113S.

Fox AD, Kripke SA, Berman JR, et al. Reduction of the severity of enterocolitis by glutamine-supplemented enteral diets. Surg Forum. 1987;38:43–44.

Fujita T, Sakurai K. Efficacy of glutamine-enriched enteral nutrition in an experimental model of mucosal ulcerative colitis. Br J Surg. 1995;82:749–751.

van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet. 1993;341:1363–1365.

Akobeng AK, Miller V, Stanton J, et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr. 2000;30:78–84.

Den Hond E, Hiele M, Peeters M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr. 1999;23:7–11.

van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet. 1993;341:1363–1365.

Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001;48:28–33.

Shabert JK, Winslow C, Lacey JM, et al. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999;15:860–864.

Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000;24:133–139.

Rohde T, MacLean DA, Hartkopp A, et al. The immune system and serum glutamine during a triathlon. Eur J Appl Physiol. 1996;74:428–434.

Rowbottom DG, Keast D, Morton AR. The emerging role of glutamine as an indicator of exercise stress and overtraining. Sports Med. 1996;21:80–97.

Castell LM, Newsholme EA. Glutamine and the effects of exhaustive exercise upon the immune response. Can J Physiol Pharmacol. 1998;76:524–532.

Castell LM, Newsholme EA. The effects of oral glutamine supplementation on athletes after prolonged, exhaustive exercise. Nutrition. 1997;13:738–742.

Mackinnon LT, Hooper SL. Plasma glutamine and upper respiratory tract infection during intensified training in swimmers. Med Sci Sports Exerc. 1996;28:285–290.

Castell LM, Poortmans JR, Newsholme EA. Does glutamine have a role in reducing infections in athletes? Eur J Appl Physiol Occup Physiol. 1996;73:488–490.

Griffiths RD, Jones C, Palmer TE. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition. 1997;13:295–302.

Shabert JK, Winslow C, Lacey JM, et al. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999;15:860–864.

Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000;24:133–139.

Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001;48:28–33.

Bozzetti F, Biganzoli L, Gavazzi C, et al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition. 1997;13:748–751.

van der Hulst, RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet.1993;341:1363–1365.

Den Hond ED, Hiele M, Peeters M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr. 1999;23:7–11.

Akobeng AK, Miller V, Stanton J, et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr. 2000;30:78–84.

Mebane AH. L-Glutamine and mania [letter]. Am J Psychiatry.1984;141:1302–1303.

Williams M. Immuno-protection against herpes simplex type II infection by eleutherococcus root extract. Int J Alt Complement Med. 1995;13:9–12.

Dowling EA, Redondo DR, Branch JD, et al. Effect of Eleutherococcus senticosus on submaximal and maximal exercise performance. Med Sci Sports Exerc. 1996;28:482–489.

Eschbach LF, Webster MJ, Boyd JC, et al. The Effect of Siberian Ginseng (Eleutherococcus Senticosus) on Substrate Utilization and Performance. Int J Sport Nutr Exerc Metab. 2000;10:444–451.

DiLorenzo PA. Pellagra-like syndrome associated with isoniazid therapy. Acta Derm Venereol. 1967;47:318–322.

Ishii N, Nishihara Y. Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy. J Neurol Neurosurg Psychiatry. 1985;48:628–634.

Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586–1595.

Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737–743.

Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73–82.

Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis. 1995;25:616–622.

Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255.

Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177–1184.

Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA 2000;284:1263–1270.

Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1:195–202.

Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab. 1996;9:501–509.

Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia. 1995;38:848–852.

Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol. 1998;35:61–64.

Head KA. Inositol hexaniacinate: a safer alternative to niacin. Altern Med Rev. 1996;1:176–184.

Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol. 1988;7:46–49.

Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996;45:330–334.

Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol. 1986;115:77–80.

Kellman M. Bursitis: a new chemotherapeutic approach. J Am Osteopathic Assoc. 1962;61:896–903.

Sperduto RD, Hu TS, Milton RC, et al. The Linxian cataract studies. Two nutrition intervention trials. Arch Ophthamol. 1993;111:1246–1253.

Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am JEpidemiol. 1996;143:1244–1256.

Tang AM, Graham NHM, Kirby AJ, et al. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men. Am JEpidemiol. 1993;138:937–951.

Doyle W, Crawford MA, Wynn AH, et al. The association between maternal diet and birth dimensions. J Nutr Med. 1990;1:9–17.

Kunin RA. Manganese and niacin in the treatment of drug-induced tardive dyskinesias. J Orthomol Psychiatry 5:4-27, 1976. In: Werbach MR. Nutritional Influences on Illness [book on CD-ROM] . 2nd ed. Tarzana, CA. 1996.

Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586–1595.

Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737–743.

Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73–82.

Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis. 1995;25:616–622.

Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA. 2000;284:1263–1270.

Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1:195–202.

Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255.

Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA 2000;284:1263–1270.

Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab. 1996;9:501–509.

Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes. 1998;47:980–984.

Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia. 1995;38:848–852.

Ludvigsson J, Samuelsson U, Johansson C, et al. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev. 2001;17:131–136.

Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol. 1998;35:61–64.

O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract. 1988;42:377–383.

Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. Br J Clin Pract. 1988;42:141–145.

Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner. 1986;230:49–54.

Tyson VC. Treatment of intermittent claudication. Practitioner. 1979;223:121–126.

O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract. 1988;42:377–383.

Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996;45:330–334.

Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol. 1988;7:46–49.

Gibbons LW, Gonzalez V, Gordon N, at al. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med. 1995;99:378–385.

Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 1999:1507.

Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA. 2000;284:1263–1270.

Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73:25D–29D.

Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J Am Coll Cardiol. 2000;35(suppl A):326.

Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 2001;87:476–479.

Bourgeois BFD, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. Neurology. 1982;32:1122–1126.

Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B 6 , Folate, Vitamin B 12 , Pantothenic Acid, Biotin, and Choline (1998). Available at www.nap.edu. Accessed October 4, 2001.

Oakley GP Jr, Adams MJ, Dickinson CM. More folic acid for everyone, now. J Nutr. 1996;126:751S–755S.

Werbach MR. Foundations of Nutritional Medicine: A Sourcebook of Clinical Research. Tarzana, CA: Third Line Press; 1997:55–57.

Senti FR, Pilch SM. Analysis of folate data from the second National Health and Nutrition Examination Survey (NHANES II). J Nutr. 1985;115:1398–1402.

Hoppner K, Lampi B. Bioavailability of folate following ingestion of cholestyramine in the rat. Int J Vitam Nutr Res. 1991;61:130–134.

West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975;16:93–98.

Hendel J, Dam M, Gram L, et al. The effects of carbamazepine and valproate on folate metabolism in man. Acta Neurol Scand. 1984;69:226–231.

Reynolds EH, Milner G, Matthews DM, et al. Anticonvulsant therapy, megaloblastic haemopoiesis and folic acid metabolism. QJM. 1966;35:521–537.

Lewis DP, Van Dyke DC, Stumbo PJ, et al. Drug and environmental factors associated with adverse pregnancy outcomes. Part I: Antiepileptic drugs, contraceptives, smoking, and folate. Ann Pharmacother. 1998;32:802–817.

Lewis DP, Van Dyke DC, Willhite LA, et al. Phenytoin-folic acid interaction. Ann Pharmacother.1995;29:726–735.

Berg MJ, Stumbo PJ, Chenard CA, et al. Folic acid improves phenytoin pharmacokinetics. J Am Diet Assoc. 1995;95:352–356.

Ono H, Sakamoto A, Eguchi T, et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism. 1997;46:959–962.

Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci. 1997;145:109–112.

Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol. 1984;18:211–216.

Baum CL, Selhub J, Rosenberg IH. Antifolate actions of sulfasalazine on intact lymphocytes. J Lab Clin Med. 1981;97:779–784.

Selhub J, Dhar GJ, Rosenberg IH. Inhibition of folate enzymes by sulfasalazine. J Clin Invest. 1978;61:221–224.

Krogh Jensen M, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest. 1996;56:421–429.

Baggott JE, Morgan SL, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J.1992;282(Pt 1):197–202.

Lawrence VA, Loewenstein JE, Eichner ER. Aspirin and folate binding: in vivo and in vitro studies of serum binding and urinary excretion of endogenous folate. J Lab Clin Med. 1984;103:944–948.

Lieberman FL, Bateman JR. Megaloblastic anemia possibly induced by triamterene in patients with alcoholic cirrhosis. Ann Intern Med.1968;68:168–173.

Mason JB, Zimmerman J, Otradovec CL, et al. Chronic diuretic therapy with moderate doses of triamterene is not associated with folate deficiency. J Lab Clin Med. 1991;117:365–369.

Amos RJ, Amess JA, Hinds CJ, et al. Investigations into the effect of nitrous oxide anaesthesia on folate metabolism in patients receiving intensive care. Chemioterapia.1985;4:393–399.

Ermens AA, Refsum H, Rupreht J, et al. Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocysteine and folate in plasma and urine. Clin Pharmacol Ther. 1991;49:385–393.

Amos RJ, Amess JA, Hinds CJ, et al. Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care. Lancet. 1982;2:835–838.

Koblin DD, Tomerson BW, Waldman FM, et al. Effect of nitrous oxide on folate and vitamin B 12 metabolism in patients. Anesth Analg. 1990;71:610–617.

Nunn JF, Chanarin I, Tanner AG, et al. Megaloblastic bone marrow changes after repeated nitrous oxide anaesthesia. Reversal with folinic acid. Br J Anaesth. 1986;58:1469–1470.

Kahn SB, Fein SA, Brodsky I. Effects of trimethoprim on folate metabolism in man. Clin Pharmacol Ther. 1968;9:550–560.

Vinnicombe HG, Derrick JP. Dihydropteroate synthase from Streptococcus pneumoniae: characterization of substrate binding order and sulfonamide inhibition. Biochem Biophys Res Commun.1999;258:752–757.

Russell RM, Golner BB, Krasinski SD, et al. Effect of antacid and H 2 receptor antagonists on the intestinal absorption of folic acid. J Lab Clin Med. 1988;112:458–463.

Stumm W, Morgan JJ. Aquatic Chemistry: An Introduction Emphasizing Chemical Equilibria in Natural Waters. 2nd ed. New York, NY: Wiley; 1981:240.

Deleu D, Louon A, Sivagnanam S, et al. Long-term effects of nitrous oxide anaesthesia on laboratory and clinical parameters in elderly Omani patients: a randomized double-blind study. J Clin Pharm Ther. 2000;25:271–277.

Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–1614.

Steegers-Theunissen RPM, Van Rossum JM, Steegers EAP, et al. Sub-50 oral contraceptives affect folate kinetics. Gynecol Obstet Invest.1993;36:230–233.

Mooij PNM, Thomas CMG, Doesburg WH, et al. Multivitamin supplementation in oral contraceptive users. Contraception. 1991;44:277–288.

Green TJ, Houghton LA, Donovan U, et al. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J Am Diet Assoc. 1998;98:49–55.

Russell RM, Dutta SK, Oaks EV, et al. Impairment of folic acid absorption by oral pancreatic extracts. Dig Dis Sci. 1980;25:369–373.

Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 1993;269:1257–1261.

Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989;262:2847–2852.

Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–1614.

Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364.

Moghadasian MH, McManus BM, Frolich JJ. Homocyst(e)ine and coronary artery disease. Arch Intern Med. 1997;157:2299–2308.

Ubbink JB, van der Merwe A, Vermaak WJH, et al. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig. 1993;71:993–998.

den Heijer M, Brouwer IA, Bos GMJ, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998;18:356–361.

Ward M, McNulty H, McPartlin J, et al. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM. 1997;90:519–524.

Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781.

Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998;158:862–867.

Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001;161:695–700.

Oakley GP Jr, Adams MJ, Dickinson CM. More folic acid for everyone, now. J Nutr. 1996;126:751S–755S.

Godfrey PSA, Toone BK, Carney MWP, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392–395.

Botez MI. Folate deficiency and neurological disorders in adults. Med Hypotheses. 1976;2:135–140.

Alpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev. 1997;55:145–149.

Passeri M, Cucinotta D, Abate G, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multicenter study. Aging (Milano). 1993;5:63–71.

Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord. 1989;16:103–107.

Heseker H, Kübler W, Pudel V, et al. Psychological disorders as early symptoms of a mild-to-moderate vitamin deficiency. Ann N Y Acad Sci. 1992;669:352–357.

Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders. Clinical potential. Drugs. 1993;45:623–636.

Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60:121–130.

Butterworth CE Jr. Effect of folate on cervical cancer. Synergism among risk factors. Ann N Y Acad Sci. 1992;669:293–299.

Kim Y-I, Mason JB. Folate, epithelial dysplasia and colon cancer. Proc Assoc Am Physicians. 1995;107:218–227.

Heimburger DC. Localized deficiencies of folic acid in aerodigestive tissues. Ann N Y Acad Sci. 1992;669:87–96.

Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA. 1999;281:1632–1637.

Stolzenberg-Solomon RZ, Pietinen P, Barrett MJ, et al. Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers. Am J Epidemiol. 2001;153:680–687.

Heimburger DC. Localized deficiencies of folic acid in aerodigestive tissues. Ann N Y Acad Sci. 1992;669:87–96.

Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst; 1993;85:875–884.

Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med. 1998;129:517–524.

Baron JA, Sandler RS, Haile RW, et al. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst. 1998;90:57–62.

Butterworth CE Jr, Hatch KD, Gore H, et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr. 1982;35:73–82.

Butterworth CE Jr, Hatch KD, Soong SJ, et al. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. Am J Obstet Gynecol. 1992;166:803–809.56.

Snowdon DA, Tully CL, Smith CD, et al. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun Study. Am J Clin Nutr. 2000;71:993–998.

van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515–1524.

Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833–841.

Griffith SM, Fisher J, Clarke S, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford). 2000;39:1102–1109.

Hunt PG, Rose CD, McIlvain-Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol. 1997;24:2230–2232.

Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993;28:466–469.

Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 2001;104:1119–1123.

Oster KA. Evaluation of serum cholesterol reduction and xanthine oxidase inhibition in the treatment of atherosclerosis. Recent Adv Stud Cardiac Struct Metab. 1973;3:73–80.

Flouvier B, Devulder B. Folic acid, xanthine oxidase, and uric acid [letter]. Ann Intern Med. 1978;88:269.

O'Keeffe ST. Restless legs syndrome. A review. Arch Intern Med. 1996;156:243–248.

Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism. 1985;34:1073–1077.

Flynn MA, Irvin W, Krause G. The effect of folate and cobalamin on osteoarthritic hands. J Am Coll Nutr. 1994;13:351–356.

Kremer JM, Bigaouette J. Nutrient intake of patients with rheumatoid arthritis is deficient in pyridoxine, zinc, copper, and magnesium. J Rheumatol. 1996;23:990–994.

Montes LF, Diaz ML, Lajous J, et al. Folic acid and vitamin B 12 in vitiligo: a nutritional approach. Cutis. 1992;50:39–42.

Coppen A, Abou-Saleh MT. Plasma folate and affective morbidity during long-term lithium therapy. Br J Psychiatry. 1982;141:87–89.

Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. JAffect Disord. 1986;10:9–13.

Callaghan TJ. The effect of folic acid on seborrheic dermatitis. Cutis. 1967;3:583–588.

Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol (Stockh). 1997;77:460–462.

Kim SM, Kim YK, Hann S-K. Serum levels of folic acid and vitamin B12 in Korean patients with vitiligo. Yonsei Med J. 1999;40:195–198.

Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 1993;269:1257–1261.

Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989;262:2847–2852.

Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–1614.

Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364.

Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project . JAMA. 1997;277:1775–1781.

Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998;158:862–867.

Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Arch Intern Med. 1997;157:2299–2308.

Ubbink JB, van der Merwe A, Vermaak WJH, et al. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig. 1993;71:993–998.

den Heijer M, Brouwer IA, Bos GMJ, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998;18:356–361.

Ward M, McNulty H, McPartlin J, et al. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM. 1997;90:519–524.

Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998;158:862–867.

Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001;161:695–700.

Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001;161:695–700.

Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60:121–130.

van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515–1524.

Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833–841.

Griffith SM, Fisher J, Clarke S, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford). 2000;39:1102–1109.

Hunt PG, Rose CD, McIlvain-Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol. 1997;24:2230–2232.

Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993;28:466–469.

Butterworth CE Jr, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989;50:353–358.

Lewis DP, Van Dyke DC, Willhite LA, et al. Phenytoin-folic acid interaction. Ann Pharmacother. 1995;29:726–735.

Berg MJ, Stumbo PJ, Chenard CA, et al. Folic acid improves phenytoin pharmacokinetics. J Am Diet Assoc. 1995;95:352–356.

Ono H, Sakamoto A, Eguchi T, et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism. 1997;46:959–962.

Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci. 1997;145:109–112.

Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B 6 , Folate, Vitamin B 12 , Pantothenic Acid, Biotin, and Choline (1998). Available at www.nap.edu. Accessed October 4, 2001.

Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis. 1984;50:73–83.

Angelico M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinaemic patients after treatment with pantethine: a crossover, double-blind trial versus placebo. Curr Ther Res. 1983;33:1091-1097.

Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol. 1986;24:630–637.

Arsenio L, Caronna S, Lateana M, et al. Hyperlipidemia, diabetes and atherosclerosis: Efficacy of treatment with pantethine [in Italian, English abstract]. Acta Biomed Ateneo Parmense. 1984;55:25–42.

Donati C, Barbi G, Cairo G, et al. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: Results of a multicenter clinical trial. Clin Nephrol. 1986;25:70–74.

Donati C, Bertieri RS, Barbi G. Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients [in Italian, English abstract]. Clin Ter. 1989;128:411–422.

Coronel G, Tornero F, Torrente J, et al. Treatment of hyperlipidemia in diabetic patients on dialysis with a physiological substance. Am J Nephrol. 1991;11:32–36.

[No authors listed]. Calcium pantothenate in arthritic conditions. A report from the General Practitioner Research Group. Practitioner. 1980;224:208–211.

Barton-Wright EC, Elliott WA. The pantothenic acid metabolism of rheumatoid arthritis. Lancet. 1963;2:862–863.

Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis. 1984;50:73–83.

Angelico M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinaemic patients after treatment with pantethine: a crossover, double-blind trial versus placebo. Curr Ther Res. 1983;33:1091-1097.

Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol. 1986;24:630–637.

Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis. 1984;50:73–83.

Rubba R, Postiglione A, De Simone B, et al. Comparative evaluation of the lipid-lowering effects of fenofibrate and pantethine in type II hyperlipoproteinemia. Curr Ther Res. 1985;38:719–727.

Da Col PG, Cattin L, Fonda M, et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Curr Ther Res. 1984;36:314–322.

Arsenio L, Caronna S, Lateana M, et al. Hyperlipidemia, diabetes and atherosclerosis: Efficacy of treatment with pantethine [in Italian, English abstract]. Acta Biomed Ateneo Parmense. 1984;55:25–42.

Donati C, Barbi G, Cairo G, et al. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: Results of a multicenter clinical trial. Clin Nephrol. 1986;25:70–74.

Donati C, Bertieri RS, Barbi G. Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients [in Italian, English abstract]. Clin Ter. 1989;128:411–422.

Coronel G, Tornero F, Torrente J, et al. Treatment of hyperlipidemia in diabetic patients on dialysis with a physiological substance. Am J Nephrol. 1991;11:32–36.

Carrara P, Matturri L, Galbussera M, et al. Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. Atherosclerosis. 1984;53:255–264.

Barton-Wright EC, Elliott WA. The pantothenic acid metabolism of rheumatoid arthritis. Lancet. 1963;2:862–863.

[No authors listed]. Calcium pantothenate in arthritic conditions. A report from the General Practitioner Research Group. Practitioner. 1980;224:208–211.